Ascendis Pharma (ASND) Misses Q3 EPS by EUR0.04

Ascendis Pharma (NASDAQ: ASND) reported Q3 EPS of (EUR0.72), EUR0.04 worse than the analyst estimate of (EUR0.68).

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Ares Management, L.P. (ARES) PT Raised to $153 at TD Cowen
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance